Falcigo Sp 50/500/25 Mg Tablet 4
4 Tablet(s) in StripMRP ₹215.52
₹183.19
15% OFF
Made by
ZYDUS HEALTHCARE LIMITED
Dosage
TABLET
Expiry
Product Summary
| Salt Content | Sulfadoxine(500.0 Mg)+Pyrimethamine(25.0 Mg)+Artesunate(50.0 Mg) |
| Uses | Acute Malaria |
| Therapy | Anti-malarial |
| Side effects | Headache, Dizziness, Myalgia, Anorexia, Arthalgia |
Assurance
available
Regulated
Medical Description
Uses
- Malaria
Contraindications
- Hypersensitivity to any of the three medicines in this product
- Sulfonamide allergy or intolerance
- Megaloblastic anaemia
- Severe impairment of kidney or liver function
Side effects
- Headache
- Dizziness
- Vertigo
- Anaemia
- Myalgia ( muscle weakness)
Precautions and Warnings
Pregnancy
Breast Feeding
Driving
Alcohol
Other General Warnings
- You have allergies
- You have anaemia
- You have liver disease
- You have kidney disease
Directions for Use
Storage and disposal
- Store below 30° C.
- Keep away from children
- Store in a cool dry place, away from moisture and excessive heat
Dosage
Overdose
Missed a Dose
Mode of Action
How Does It Work?
Interactions
Interactions with other medicines
Other general Interactions
Frequently Asked Questions (FAQs)
Articles
View All
Chronic Condition Articles
View All
Did you find this helpful?
Explore More at Pharmeasy
Manufacturer Details
Brand:FALCIGO SP
Vendor Details
Fulfillment Information: Falcigo Sp 50/500/25 Mg Tablet 4 will be delivered by a licensed retail pharmacy nearest to your location. Order acceptance and fulfillment are dependent upon the verification of your doctor's valid prescription (where applicable) and the current stock of this medicine.
References:
- Artesunate+Sulfadoxine/Pyrimethamine Summary of Product Characteristics (SmPC) [Internet]. extranet.who.int Guilin Pharmaceutical Co. Ltd.; 2022. [cited 8 March 2022]. Available from : https://extranet.who.int/pqweb/sites/default/files/MA066part3v3.pdf
- Artesunate for injection. [Internet] Acessdata.fda.gov. 2022 [cited 8 March 2022] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf
- Daraprim Tablets (Pyrimethamine) - Summary of Product Characteristics (SmPC) - (emc) [Internet] Medicines.org.uk. 2022 [cited 8 March 2022] Available from : https://www.medicines.org.uk/emc/product/938/smpc#gref
In Case of Any Issues Contact Us
Email Id:care@pharmeasy.in
Phone Number:7666100300
Address:D-37/1, Opp. Sandoz, TTC Industrial Area, MIDC Industrial Area, Turbhe, Navi Mumbai, Maharashtra 400703
Disclaimer
The information provided herein is supplied to the best of our abilities to make it accurate and reliable as it is published after a review by a team of professionals. This information is solely intended to provide a general overview on the product and must be used for informational purposes only. You should not use the information provided herein to diagnose, prevent, or cure a health problem. Nothing contained on this page is intended to create a doctor-patient relationship, replace or be a substitute for a registered medical practitioner's medical treatment/advice or consultation. The absence of any information or warning to any medicine shall not be considered and assumed as an implied assurance. We highly recommend that you consult your registered medical practitioner for all queries or doubts related to your medical condition. You hereby agree that you shall not make any health or medical-related decision based in whole or in part on anything contained in the Site. Please click here for detailed T&C.
